Until the advent of immune checkpoint inhibitors (ICIs), definitive radiotherapy (RT)
concurrently with chemotherapy was recommended for unresectable, locally advanced non …

Immunotherapy has radically changed the clinical management of patients with cancer in
recent years. Immune checkpoint inhibitors (ICIs) reversing the immunosuppressive effects …

Lately, the success of ICIs has drastically changed the landscape of cancer treatment, and
several immune checkpoint inhibitors (ICIs) have been approved by the US Food and Drug …

For many years, conventional oncologic treatments such as surgery, chemotherapy, and
radiotherapy (RT) have dominated the field of non-small-cell lung cancer (NSCLC). The …

Immune-checkpoint inhibitors (ICI) have dramatically changed the landscape of lung cancer
treatment. Preclinical studies investigating combination of ICI with radiation show a …

Background It is now widely accepted that radiotherapy (RT) can provoke a systemic
immune response, which gives a strong rationale for the combination of RT and immune …

Purpose In the era of immunotherapy, the treatment for bulky, locally advanced non-small
cell lung cancer (LA-NSCLC) remains challenging. This study explored the feasibility of …

Non-small cell lung cancer (NSCLC) is a common and lethal malignancy. The recent
development of immune checkpoint inhibitors has afforded a durable, dramatic treatment …

Lung cancer is one of the main causes of cancer-related mortality worldwide. Over the years,
different therapeutic modalities have been adopted depending on tumor stage and patient …

Concurrent chemoradiation (cCRT) with platinum-based chemotherapy is standard-of-care
therapy for patients with stage III unresectable non–small cell lung cancer (NSCLC) …